(Total Views: 510)
Posted On: 06/05/2019 2:09:20 AM
Post# of 154994
New video on with proactive investors .,,
-0:40. About mono pivotal , 525 mg is as good or better than 700 so we will go with that , 525 mg .,,
We talking with FDA
we submitted our final protocol now..
-2:45 Dr RP talking very little about GvHD and NASH and TNBC ,
4:15 Dr Np , everyone is looking on mono , we have potential in doing licensing and partnership
4:00 Dr RP , ...things what excites me the most is no serious side effect in Leronlimab
5:50 ,Dr RP , new way of attacking cancer , to attack in the blood stream , and we measure CTC...
6.00 Dr RP , In stead of thinking about cancer as primary disease ,
we thinking more about circulation of those cancer cells in blood stream and attacking them there.
Dr Pestell did talk about Merck and Pfizer couple of times ,
My first choice for us is still Pfizer !!!!!!
And few times Dr RP talked how we don't see serious side effects with Leronlimab....
-0:40. About mono pivotal , 525 mg is as good or better than 700 so we will go with that , 525 mg .,,
We talking with FDA
we submitted our final protocol now..
-2:45 Dr RP talking very little about GvHD and NASH and TNBC ,
4:15 Dr Np , everyone is looking on mono , we have potential in doing licensing and partnership
4:00 Dr RP , ...things what excites me the most is no serious side effect in Leronlimab
5:50 ,Dr RP , new way of attacking cancer , to attack in the blood stream , and we measure CTC...
6.00 Dr RP , In stead of thinking about cancer as primary disease ,
we thinking more about circulation of those cancer cells in blood stream and attacking them there.
Dr Pestell did talk about Merck and Pfizer couple of times ,
My first choice for us is still Pfizer !!!!!!
And few times Dr RP talked how we don't see serious side effects with Leronlimab....
(2)
(0)
